Login
Manage Portfolio
Post a StockTalk
Write an Instablog
Get Daily Email Alert
Seeking Alpha
Home
The Macro View
Stocks & Sectors
Global Markets
ETFs
Investing Ideas
Breaking News
Transcripts
Business Intelligence
Applera Corp-Celera Genomics Group (CRA)
(
)
Quotes
Dashboard
Chart
Historical Prices
Options
Analysis
Articles
Instablogs
StockTalks
Sentiment
Comments
News & PR
Market Currents
Buzz
Twitter: CRA
Coverage
Top Authors
Cramer
Top Analysts
Business Intelligence
Transcripts
Events
Key Developments
Earnings
History & Projected
Consensus
Peer Earnings
Filings
SEC Filings
Annual Report
Ownership
Major Holders
Insider Trades
Insider Sentiment
Index Membership
Short Interest
Financials
Income Statement
Balance Sheet
Cash Flow
Company
Wikipedia Profile
Officers & Directors
Executive Comp
Analysis - Latest Articles
by
most recent
|
most commented
Combining Value and Earnings Surprises for Outsize Returns
Dec 21
•
Scott's Investments
•
Comment!
Biotech: Q3 Market Update
Oct 16
•
R. Scott Raynovich
•
1 Comment
VC Financings Boost Interest in Biotech
Jul 24
•
The Burrill Report
•
Comment!
Biotech Opportunities: Look for Decent Pipeline, Big Pharma Partnerships
Jun 2
•
Zacks.com
•
15 Comments
Two Potential Mega Biotech Deals Fuel Industry Hopes
May 31
•
The Burrill Report
•
2 Comments
Celera Corporation: Financials Improve; Challenges Ahead
May 12
•
Zacks.com
•
Comment!
Reversal of Stem Cell Research Ban: 13 Stocks to Benefit
Mar 12
•
Brian Dean
•
9 Comments
12 Stem Cell Stocks - Updated
Mar 9
•
Stockerblog
•
8 Comments
Healthcare Reform, M&A Likely to Focus on Preventative Medicine
Jan 26
•
Mike Havrilla
•
2 Comments
Nine Stem Cell Stocks to Add to Your Portfolio
Oct 2, 2007
•
Stockerblog
•
2 Comments
Biotech Day in Review: Biotech Takes a 3% Hit
Feb 28, 2007
•
Centient Biotech Investor
•
Comment!
Investing in Stem Cell Stocks: Growth Industry of the Future?
Feb 21, 2007
•
Stockerblog
•
12 Comments
Report From JPMorgan's HealthCare Conference: The Spinal Business Is Hot
Jan 10, 2007
•
Centient Biotech Investor
•
Comment!
Companies Trading Below Net Asset Value Becoming Something of a Rarity
Dec 26, 2006
•
Jon Heller
•
Comment!
Biotech IPO: Highlights from Rosetta Genomics' F1 Filing
Sep 10, 2006
•
Evelyn Rubin
•
Comment!
IPO Analysis: Perlegen and Genetically Targeted Medications (PERL)
Apr 27, 2006
•
ClearFish Research
•
Comment!